Cytosorbents Corp (CTS) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Cytosorbents Corporation on April 29, 2022. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Monmouth Junction, New Jersey. Its common stock trades on the Nasdaq Capital Market under the symbol CTSO.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than financial performance.
Material Changes and Events
Under Item 8.01 (Other Events), the Company announced the enrollment of the first patient in the Safe and Timely Antithrombotic Removal-Direct Oral Anticoagulants (STAR-D) clinical trial. Key details include:
- Trial Design: Double-blind, randomized, controlled clinical trial.
- Objective: To support FDA marketing approval of the DrugSorb®-ATR Antithrombotic Removal System.
- Application: Intraoperative removal of apixaban and rivaroxaban during cardiothoracic surgery.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the inherent uncertainties of clinical trials. The primary focus is the milestone achievement of patient enrollment.
Investor Verification Checklist
- Verify the full text of the press release included as Exhibit 99.1 for detailed trial protocols.
- Monitor future filings for patient enrollment milestones and interim data readouts from the STAR-D trial.
- Review the Company's most recent 10-K or 10-Q for current financial position and cash runway, as this 8-K does not contain financial data.